

TABLE 2 Patient demographics and low dose ketamine usage

Total cohort (n=19)	
Age, median years (IQR)	14.6 (11.9, 18.1)
Sex	7 F, 12 M
Initial median ketamine dose mg/kg/h (IQR)	0.06 (0.06, 0.16)
Median days of ketamine use (IQR)	6 (4, 11)
Patients with sickle cell disease (n=7)	
Age, median years (IQR)	14.3 (12.1, 16.9)
Sex	2 F, 5 M
Genotype	3 HbSS 2 HbSC 1 HbS β_0 1 HbS β_+
Reason for admission [^]	4 chest pain 2 back pain 2 thigh pain 1 hip pain 1 headache
Initial median ketamine dose mg/kg/h (IQR)	0.05 (0.03, 0.06)
Median days of ketamine use (IQR)	4.5 (3.8, 6.3)
Patients with cancer (n=12)	
Age, median years (IQR)	14.8 (7.2, 18.5)
Sex	5 F, 7 M
Underlying diagnosis	8 Leukemia 4 Solid tumors (1 at end-of-life)
Initial median ketamine dose mg/kg/h (IQR)	0.06 (0.06, 0.24)
Median days of ketamine use (IQR)	11 (6, 12)

[^]patients all admitted for vaso-occlusive episode, some with more than one area of pain
IQR, interquartile range